Rakovina Therapeutics Announces Receipt of AI-Derived Drug Candidates and Advancement to Preclinical Validation
VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company focused on the […]